Literature DB >> 27514753

Tetramethylpyrazine Ameliorates Rotenone-Induced Parkinson's Disease in Rats: Involvement of Its Anti-Inflammatory and Anti-Apoptotic Actions.

Haidy E Michel1, Mariane G Tadros2, Ahmed Esmat1, Amani E Khalifa1, Ahmed M Abdel-Tawab3.   

Abstract

Parkinson's disease (PD) is a slowly progressive neurodegenerative movement disorder. Apoptosis, neuroinflammation, and oxidative stress are the current hypothesized mechanisms for PD pathogenesis. Tetramethylpyrazine (TMP), the major bioactive component of Ligusticum wallichii Franchat (ChuanXiong), Family Apiaceae, reportedly has anti-apoptotic, anti-inflammatory and antioxidant effects. This study investigated the role of 'TMP' in preventing rotenone-induced neurobiological and behavioral sequelae. A preliminary dose-response study was conducted where rats received TMP (10, 20, and 40 mg/kg, i.p.) concomitantly with rotenone (2 mg/kg, s.c.) for 4 weeks. Catalepsy, locomotor activity, striatal dopamine content, and tyrosine hydroxylase "TH" and α-synuclein immunoreactivity were evaluated. The selected TMP dose (20 mg/kg) was used for western blot analysis of Bax, Bcl2, and DJ-1, immunohistochemical detection of nuclear factor kappa B (NF-кB), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX2), and glial fibrillary acidic protein (GFAP) expression, in addition to biochemical analysis of caspase-3 activity, nuclear factor erythroid 2-related factor 2 (Nrf2), and heme oxygenase-1 (HO-1) levels. Results showed that TMP (20 mg/kg) significantly improved midbrain and striatal TH expression and striatal dopamine content as well as the motor deficits, compared to rotenone-treated group. These results were correlated with reduction in caspase-3 activity and α-synuclein expression, along with improvement of midbrain and striatal Bax/Bcl2 ratio compared to rotenone-treated group. TMP also attenuated rotenone-induced upregulation of Nrf2/HO-1 pathway. Furthermore, TMP downregulated rotenone-induced neuroinflammation markers: NF-кB, iNOS, COX2, and GFAP expression in both the midbrain and striatum. Taken together, the current study suggests that TMP is entitled to, at least partially, preventing PD neurobiological and behavioral deficits by virtue of its anti-apoptotic, anti-inflammatory, and antioxidant actions.

Entities:  

Keywords:  Apoptosis; Neuroinflammation; Parkinson’s disease; Rotenone; Tetramethylpyrazine

Mesh:

Substances:

Year:  2016        PMID: 27514753     DOI: 10.1007/s12035-016-0028-7

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  86 in total

Review 1.  Astrocyte control of synaptic transmission and neurovascular coupling.

Authors:  Philip G Haydon; Giorgio Carmignoto
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

2.  Enhanced expression of iNOS intratumorally and at the immunization site after immunization with IFNgamma-secreting rat glioma cells.

Authors:  Anna C Johansson; Pontus Hegardt; Shorena Janelidze; Edward Visse; Bengt Widegren; Peter Siesjö
Journal:  J Neuroimmunol       Date:  2002-02       Impact factor: 3.478

3.  Neuroprotection by tetramethylpyrazine against ischemic brain injury in rats.

Authors:  Tsung-Kuei Kao; Yen-Chuan Ou; Jong-Song Kuo; Wen-Yin Chen; Su-Lan Liao; Ching-Wen Wu; Chun-Jung Chen; Nai-Nu Ling; Yong-Hong Zhang; Wen-Huang Peng
Journal:  Neurochem Int       Date:  2005-11-28       Impact factor: 3.921

4.  Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.

Authors:  Masatoshi Inden; Yoshihisa Kitamura; Hiroki Takeuchi; Takashi Yanagida; Kazuyuki Takata; Yuka Kobayashi; Takashi Taniguchi; Kanji Yoshimoto; Masahiko Kaneko; Yasunobu Okuma; Takahiro Taira; Hiroyoshi Ariga; Shun Shimohama
Journal:  J Neurochem       Date:  2007-06       Impact factor: 5.372

5.  Tetramethylpyrazine alleviated cytokine synthesis and dopamine deficit and improved motor dysfunction in the mice model of Parkinson's disease.

Authors:  Hong Zhao; Mei-Ling Xu; Qi Zhang; Zhao-Hui Guo; Ying Peng; Zheng-Yi Qu; Yong-Nan Li
Journal:  Neurol Sci       Date:  2014-07-17       Impact factor: 3.307

6.  Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain.

Authors:  J Zhang; C A Piantadosi
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

7.  Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells.

Authors:  Masahiko Watabe; Toshio Nakaki
Journal:  J Pharmacol Exp Ther       Date:  2007-08-28       Impact factor: 4.030

8.  Inhibition of neuroinflammation and mitochondrial dysfunctions by carbenoxolone in the rotenone model of Parkinson's disease.

Authors:  Poonam Thakur; Bimla Nehru
Journal:  Mol Neurobiol       Date:  2014-06-20       Impact factor: 5.590

9.  Neuroprotective effects of the immunomodulatory drug Setarud on cerebral ischemia in male rats.

Authors:  Farzaneh Vafaee; Nasser Zangiabadi; Fatemeh Mehdi Pour; Farzaneh Dehghanian; Majid Asadi-Shekaari; Hossein Karimi Afshar
Journal:  Neural Regen Res       Date:  2012-09-25       Impact factor: 5.135

10.  Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease.

Authors:  Heather L Martin; Matteo Santoro; Sarah Mustafa; Gernot Riedel; John V Forrester; Peter Teismann
Journal:  Glia       Date:  2015-10-29       Impact factor: 7.452

View more
  16 in total

1.  Neuroprotective Effects of Filgrastim in Rotenone-Induced Parkinson's Disease in Rats: Insights into its Anti-Inflammatory, Neurotrophic, and Antiapoptotic Effects.

Authors:  Mariama S Azmy; Esther T Menze; Reem N El-Naga; Mariane G Tadros
Journal:  Mol Neurobiol       Date:  2018-01-11       Impact factor: 5.590

2.  Protective Effect of (-)Epigallocatechin-3-gallate on Rotenone-Induced Parkinsonism-like Symptoms in Rats.

Authors:  Hsiang-Chien Tseng; Mao-Hsien Wang; Kuo-Chi Chang; Hung-Sheng Soung; Chih-Hsiang Fang; Yi-Wen Lin; Keng-Yuan Li; Chih-Chuan Yang; Cheng-Chia Tsai
Journal:  Neurotox Res       Date:  2019-12-06       Impact factor: 3.911

Review 3.  GSK-3β-mediated regulation of Nrf2/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders.

Authors:  Divya Soni; Puneet Kumar
Journal:  Pharmacol Rep       Date:  2022-07-26       Impact factor: 3.919

4.  Tetramethylpyrazine Attenuates Cognitive Impairment Via Suppressing Oxidative Stress, Neuroinflammation, and Apoptosis in Type 2 Diabetic Rats.

Authors:  Jatinder Dhaliwal; Navneet Dhaliwal; Ansab Akhtar; Anurag Kuhad; Kanwaljit Chopra
Journal:  Neurochem Res       Date:  2022-06-04       Impact factor: 4.414

Review 5.  Nrf2 as a potential target for Parkinson's disease therapy.

Authors:  Yingcai Niu; Jing Zhang; Miaoxian Dong
Journal:  J Mol Med (Berl)       Date:  2021-04-12       Impact factor: 4.599

6.  Simvastatin Inhibits Activation of NADPH Oxidase/p38 MAPK Pathway and Enhances Expression of Antioxidant Protein in Parkinson Disease Models.

Authors:  Huichun Tong; Xiuping Zhang; Xingjun Meng; Lingli Lu; Dongmei Mai; Shaogang Qu
Journal:  Front Mol Neurosci       Date:  2018-05-22       Impact factor: 5.639

7.  Herbal Medicine Formulas for Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Clinical Trials.

Authors:  Chun-Shuo Shan; Hong-Feng Zhang; Qing-Qing Xu; Yi-Hua Shi; Yong Wang; Yan Li; Yan Lin; Guo-Qing Zheng
Journal:  Front Aging Neurosci       Date:  2018-11-08       Impact factor: 5.750

8.  Cold-inducible protein RBM3 mediates hypothermic neuroprotection against neurotoxin rotenone via inhibition on MAPK signalling.

Authors:  Hai-Jie Yang; Rui-Juan Zhuang; Yuan-Bo Li; Tian Li; Xin Yuan; Bing-Bing Lei; Yun-Fei Xie; Mian Wang
Journal:  J Cell Mol Med       Date:  2019-08-22       Impact factor: 5.310

9.  Effectiveness of Yi-Zhi-An-Shen granules on cognition and sleep quality in older adults with amnestic mild cognitive impairment: protocol for a randomized, double-blind, placebo-controlled trial.

Authors:  Shengnan Yue; Ting He; Baiyang Li; Yanqin Qu; Hongmei Peng; Jinxin Chen; Ming Lei; Chongli Chen; Wenbin Wu
Journal:  Trials       Date:  2019-08-20       Impact factor: 2.279

Review 10.  The Roles of Tetramethylpyrazine During Neurodegenerative Disease.

Authors:  Zeyu Meng; Huize Chen; Shengxi Meng
Journal:  Neurotox Res       Date:  2021-08-05       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.